UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER
SECTION 12(g) OF
THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE
REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934.
Commission
File Number 001-36498
|
CELLULAR BIOMEDICINE GROUP, INC.
|
|
(Exact
name of registrant as specified in its charter)
|
|
9605 Medical Center Drive, Suite 100
Rockville, Maryland 20850
(301) 825-5320
|
|
(Address,
including zip code, and telephone number, including area code, of
registrant’s principal executive offices)
|
|
Common Stock, par value $0.001 per share
|
|
(Title
of each class of securities covered by this Form)
|
|
None
|
|
(Titles
of all other classes of securities for which a duty to file reports
under Section 13(a) or 15(d) remains)
|
Please
place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file
reports:
|
Rule
12g-4(a)(1)
|
☒
|
|
Rule
12g-4(a)(2)
|
☐
|
|
Rule
12h-3(b)(1)(i)
|
☒
|
|
Rule
12h-3(b)(1)(ii)
|
☐
|
|
Rule
15d-6
|
☐
|
|
Rule
15d-22(b)
|
☐
|
Approximate number
of holders of record as of the certification or notice date: One
(1) holder.
Pursuant to the
requirements of the Securities Exchange Act of 1934, Cellular
Biomedicine Group, Inc. has caused this certification/notice to be
signed on its behalf by the undersigned duly authorized
person.